FLGTFulgent Genetics, Inc.
Price
-7.8%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, a flag to check, growth steady, the market with it.
Charts
As reported to the SEC, without any scoring.
Fulgent Genetics, Inc. (FLGT) reported revenue of $85M in Q2 2026 (quarter ended Jun 30, 2026), up 4.4% from the same quarter a year earlier. That came with a gross margin of 30% and net loss of $30M. For the full year FY2025, revenue was $323M (+14% year on year) and net income −$61M. The next results filing is expected around Nov 6, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 30, 2026Fulgent Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jun 2, 2026On June 1, 2026, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing that the Company will present updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session based on the Company's full abstract entitled …Other event · Form 8-K
- May 21, 2026On May 21, 2026, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing that the Company's full abstract entitled “FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020”, presenting interim data from the Company's …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
Ranks #14 of 21 by RyuScore